EA200500244A1 - Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии - Google Patents

Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии

Info

Publication number
EA200500244A1
EA200500244A1 EA200500244A EA200500244A EA200500244A1 EA 200500244 A1 EA200500244 A1 EA 200500244A1 EA 200500244 A EA200500244 A EA 200500244A EA 200500244 A EA200500244 A EA 200500244A EA 200500244 A1 EA200500244 A1 EA 200500244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tetratiomolybdat
tetrapropilammonia
compounds
related compounds
antiangiogenic therapy
Prior art date
Application number
EA200500244A
Other languages
English (en)
Other versions
EA008683B1 (ru
Inventor
Джордж Дж. Бревер
София Д. Мерайвер
Димитрий Коукоуванис
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Publication of EA200500244A1 publication Critical patent/EA200500244A1/ru
Publication of EA008683B1 publication Critical patent/EA008683B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Раскрыты соединения, связывающие медь, с усовершенствованными свойствами и способы применения таких соединений для предупреждения и лечения ангиогенных заболеваний, как, например, рака. Преимущества изобретения включают повышенную стабильность соединений, которая достигается без снижения эффективности. Также предложены фармацевтические композиции, терапевтические наборы, способы комбинированного лечения и применение.Отчет о международном поиске был опубликован 2004.04.08.
EA200500244A 2002-07-23 2003-07-23 Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии EA008683B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39780402P 2002-07-23 2002-07-23
PCT/US2003/022914 WO2004009072A2 (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

Publications (2)

Publication Number Publication Date
EA200500244A1 true EA200500244A1 (ru) 2005-12-29
EA008683B1 EA008683B1 (ru) 2007-06-29

Family

ID=30771119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500244A EA008683B1 (ru) 2002-07-23 2003-07-23 Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии

Country Status (16)

Country Link
US (1) US7888389B2 (ru)
EP (1) EP1539131A4 (ru)
JP (1) JP2005538093A (ru)
KR (1) KR20050025976A (ru)
CN (1) CN1688303A (ru)
AU (1) AU2003261222B2 (ru)
BR (1) BR0312845A (ru)
CA (1) CA2493341A1 (ru)
EA (1) EA008683B1 (ru)
GE (1) GEP20074270B (ru)
IL (1) IL166385A0 (ru)
MX (1) MXPA05000875A (ru)
NO (1) NO20050902L (ru)
NZ (1) NZ537896A (ru)
WO (1) WO2004009072A2 (ru)
ZA (1) ZA200501162B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
EP1115389B1 (en) * 1998-09-25 2014-03-12 PhilERA New Zealand Limited Fructosamine oxidase: antagonists and inhibitors
WO2003077901A1 (en) * 2002-03-08 2003-09-25 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US20070292533A1 (en) * 2002-05-24 2007-12-20 Regents Of The University Of Michigan Copper lowering treatment of autoimmune diseases
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
JP2005538093A (ja) 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
WO2004017956A1 (en) * 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
RU2002128364A (ru) * 2002-10-23 2004-04-27 Институт нефтехимического синтеза РАН им. А.В. Топчиева Способ получения присадки к смазочным материалам (варианты)
BRPI0410651A (pt) * 2003-05-27 2006-07-04 Attenuon Llc composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
EP1729784A1 (en) * 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
EP1721010A2 (en) * 2004-02-24 2006-11-15 Attenuon, LLC Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
DK1778618T3 (da) 2004-07-19 2014-03-10 Philera New Zealand Ltd Syntese af triethylentetraminer
WO2006044779A1 (en) * 2004-10-14 2006-04-27 Northwestern University Detection and treatment of renal cancer
US7893289B2 (en) * 2007-02-21 2011-02-22 Ssv Therapeutics, Inc. Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids
WO2009009622A2 (en) * 2007-07-09 2009-01-15 Pipex Pharmaceuticals, Inc. Pharmaceutical compositions, including attm, and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US20100312139A1 (en) * 2009-06-04 2010-12-09 Board Of Regents Of The University Of Texas System Method for Identifying Mammals at Risk for Elevated intracranial Pressure
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
US20160220500A1 (en) * 2014-11-14 2016-08-04 Kent State University Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer
CN107530311A (zh) 2015-02-03 2018-01-02 卡德门制药有限公司 稳定的曲恩汀制剂
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
JP2023549037A (ja) 2020-10-07 2023-11-22 シーティーアイ バスキュラー アーゲー 生物活性型に変換可能なデバイスおよび関連する方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909541A (en) 1955-01-07 1959-10-20 Inst Francais Du Petrole Nitrogenous thiomolybdates
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4343746A (en) 1980-12-10 1982-08-10 Gulf Research & Development Company Quaternary ammonium thiomolybdates
US4762705A (en) 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
US4952607A (en) 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US4430443A (en) 1982-07-20 1984-02-07 Exxon Research And Engineering Co. Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use
US4766226A (en) 1984-02-01 1988-08-23 Smithkline Beckman Corporation Antitumor pharmaceutical compositions and methods for treating tumors employing α,ω-bis(disubstitutedphosphino)hydrocarbon derivatives or [α, ω-bis(disubstitutedphosphino)hydrocarbon] di
DE3586683T2 (de) 1984-12-18 1993-04-08 Clark Pharma Dev Antitumorzusammensetzungen enthaltend ein reaktionsprodukt zwischen einem cytotoxischen aldehyd und penicillamin und deren verwendung zur herstellung von arzneimitteln.
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4604278A (en) * 1985-05-17 1986-08-05 Gte Products Corporation Production of ammonium tetrathiomolybdate
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5162231A (en) 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
US5057302A (en) 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5385933A (en) 1989-02-27 1995-01-31 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof
US5100885A (en) 1989-08-01 1992-03-31 Johnson Matthey, Inc. Copper radiosensitizers
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
MX172248B (es) 1989-12-20 1993-12-09 Univ Mexico Procedimiento para la obtencion de nuevos complejos aminoacidatos de cobre mixtos a base de fenantrolinas feniladas como agentes anticancerigenos
US5972922A (en) 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
AU682149B2 (en) 1992-06-19 1997-09-25 Medical College Of Ohio, The Production and use of imines of porphyrins
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5563132A (en) 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
DK0814861T3 (da) 1995-03-14 2002-10-07 Siemens Ag Udskiftelig præcisionsdoseringsenhed til ultralydforstøveranordning
DK0814860T3 (da) 1995-03-14 2000-05-08 Siemens Ag Ultrasonisk forstøveranordning med aftagelig præcisionsdoseringsendhed
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
EP1234585A3 (en) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
WO2000013712A2 (en) 1998-09-04 2000-03-16 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
CA2458622A1 (en) * 2001-08-24 2003-03-06 Maine Medical Center Research Institute Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
EP1531827A4 (en) * 2002-05-24 2009-07-08 Univ Michigan COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES
US7189865B2 (en) 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
JP2005538093A (ja) 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物

Also Published As

Publication number Publication date
NO20050902L (no) 2005-04-19
ZA200501162B (en) 2005-09-05
CN1688303A (zh) 2005-10-26
US7888389B2 (en) 2011-02-15
NZ537896A (en) 2007-12-21
WO2004009072B1 (en) 2004-07-08
GEP20074270B (en) 2007-12-25
AU2003261222A1 (en) 2004-02-09
EP1539131A4 (en) 2009-07-08
MXPA05000875A (es) 2005-09-30
WO2004009072A3 (en) 2004-04-08
US20040259945A1 (en) 2004-12-23
WO2004009072A2 (en) 2004-01-29
EA008683B1 (ru) 2007-06-29
AU2003261222B2 (en) 2009-07-09
EP1539131A2 (en) 2005-06-15
CA2493341A1 (en) 2004-01-29
IL166385A0 (en) 2006-01-16
BR0312845A (pt) 2005-06-07
JP2005538093A (ja) 2005-12-15
KR20050025976A (ko) 2005-03-14

Similar Documents

Publication Publication Date Title
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA201691142A1 (ru) Ингибиторы мек и способы их применения
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
EA200700225A1 (ru) Аналоги тетрапептида
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
GB0223040D0 (en) Therapeutic compounds
EA200201214A1 (ru) Замещенные тиоацетамиды
CY1107985T1 (el) Ccr1 ανταγωνιστες για την αγωγη μεταξυ αλλων απομυελινωτικης φλεγμονωδους νοσου
EA200500849A1 (ru) Новые соединения лапахона и способы их применения
EA200500782A1 (ru) Лечение геморрагического шока
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU